Omics sciences and precision medicine in lung cancer
Abstract: Lung cancer is a complex disease, with a wide range of genetic alterations and clinical presentations. Understanding the natural and clinical history of the disease is crucial for developing effective diagnostic and treatment strategies. Omics approaches, such as genomics, transcriptomics, proteomics, and metabolomics, have emerged as powerful tools for understanding the molecular mechanisms underlying lung cancer and for identifying novel biomarkers and therapeutic targets. These approaches enable researchers to examine the entire genome, transcriptome, proteome, or metabolome of a cell or tissue, providing a comprehensive view of the biological processes involved in lung cancer development and progression. Targeted therapies that address specific genetic mutations and pathways hold promise for improving the diagnosis and treatment of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
La Clinica terapeutica - 174(2023), Suppl 2(6) vom: 15. Nov., Seite 37-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Micheletti, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genetics |
|---|
| Anmerkungen: |
Date Completed 24.11.2023 Date Revised 24.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7417/CT.2023.2470 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36486012X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36486012X | ||
| 003 | DE-627 | ||
| 005 | 20231226100359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7417/CT.2023.2470 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM36486012X | ||
| 035 | |a (NLM)37994747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Micheletti, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Omics sciences and precision medicine in lung cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Abstract: Lung cancer is a complex disease, with a wide range of genetic alterations and clinical presentations. Understanding the natural and clinical history of the disease is crucial for developing effective diagnostic and treatment strategies. Omics approaches, such as genomics, transcriptomics, proteomics, and metabolomics, have emerged as powerful tools for understanding the molecular mechanisms underlying lung cancer and for identifying novel biomarkers and therapeutic targets. These approaches enable researchers to examine the entire genome, transcriptome, proteome, or metabolome of a cell or tissue, providing a comprehensive view of the biological processes involved in lung cancer development and progression. Targeted therapies that address specific genetic mutations and pathways hold promise for improving the diagnosis and treatment of this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a genomics | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a tailored therapy | |
| 650 | 4 | |a tumor | |
| 700 | 1 | |a Dhuli, K |e verfasserin |4 aut | |
| 700 | 1 | |a Donato, K |e verfasserin |4 aut | |
| 700 | 1 | |a Gadler, M |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, S |e verfasserin |4 aut | |
| 700 | 1 | |a Guerri, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cristofoli, F |e verfasserin |4 aut | |
| 700 | 1 | |a Generali, D |e verfasserin |4 aut | |
| 700 | 1 | |a Donofrio, C A |e verfasserin |4 aut | |
| 700 | 1 | |a Cominetti, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fioravanti, A |e verfasserin |4 aut | |
| 700 | 1 | |a Riccio, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bernini, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fulcheri, E |e verfasserin |4 aut | |
| 700 | 1 | |a Stuppia, L |e verfasserin |4 aut | |
| 700 | 1 | |a Stuppia, L |e verfasserin |4 aut | |
| 700 | 1 | |a Gatta, V |e verfasserin |4 aut | |
| 700 | 1 | |a Cristoni, S |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchin, S |e verfasserin |4 aut | |
| 700 | 1 | |a Marceddu, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bertelli, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Clinica terapeutica |d 1958 |g 174(2023), Suppl 2(6) vom: 15. Nov., Seite 37-45 |w (DE-627)NLM000039187 |x 1972-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2023 |g number:Suppl 2(6) |g day:15 |g month:11 |g pages:37-45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7417/CT.2023.2470 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2023 |e Suppl 2(6) |b 15 |c 11 |h 37-45 | ||